1.1Thioether linker between fragments
A divalent sulfur atom forms a single bond to each fragment. The two bent carbon–sulfur bonds and their longer bond lengths set the spacing and orientation between the fragments.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A divalent sulfur atom forms a single bond to each fragment. The two bent carbon–sulfur bonds and their longer bond lengths set the spacing and orientation between the fragments.
Three consecutive methylene groups connect the two attachment points. Rotation about the two internal carbon–carbon bonds lets the bridge adopt extended and folded conformations.
The thiophene ring shares two adjacent carbon atoms with the neighboring ring and places sulfur at a nonfusion position. A sulfur lone pair contributes two electrons to the six-electron aromatic system of the five-membered ring.
The scaffold bonds directly to the carbonyl carbon of a –C(O)NH2 group. The carbonyl oxygen accepts hydrogen bonds, and the amide N–H bonds donate them.
The methylamino nitrogen bonds directly to the carbonyl carbon and forms a secondary amide, –C(O)NHCH3. The carbonyl oxygen accepts hydrogen bonds, and the N–H bond donates one.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A benzothiazole pyrimidineamine inhibitor serves as a reference compound in a veterinary oncology research assay. Purified canine DYRK2, a peptide substrate, and adenosine triphosphate occupy each reaction well. The assay measures peptide phosphorylation across a dilution series and normalizes the results to wells containing the same solvent concentration.
A sulfoxide group, S(O), replaces the S(O)2 linker between the same two attachment points in a benzothiazole pyrimidineamine scaffold. The corresponding thioether supplies the sulfur linkage, and controlled oxidation introduces one oxygen atom on sulfur. Liquid chromatography coupled to mass spectrometry distinguishes the sulfoxide from residual thioether and sulfone, and a chiral column separates the sulfur stereoisomers for individual DYRK2 assays.
A 384-well plate holds 20 µL reactions containing purified DYRK2, a peptide substrate, adenosine triphosphate, and a benzothiazole pyrimidineamine inhibitor. The inhibitor is dispensed in duplicate at ten concentrations in a threefold dilution series starting at 30 µM, with 0.5% dimethyl sulfoxide in every well. The assay measures adenosine diphosphate after 30 minutes at 25 °C and normalizes the signal against solvent-only and enzyme-free controls.
A microfluidic perfusion chip holds tumor spheroids in recessed chambers connected to a shared outlet. Separate pumps deliver culture medium and medium containing a benzothiazole pyrimidineamine inhibitor, and a junction mixes the streams upstream of the chambers. The pump ratio sets the inhibitor concentration at fixed total flow, and time-lapse microscopy measures spheroid area during exposure and washout.
A surface plasmon resonance flow cell carries purified DYRK2 immobilized on a sensor surface and a reference channel with the same surface chemistry. The instrument injects a concentration series of the benzothiazole pyrimidineamine inhibitor through both channels, then switches to compound-free buffer to record dissociation. Reference-channel subtraction and solvent correction yield binding responses for an equilibrium affinity fit.
A liquid handler dispenses benzothiazole pyrimidineamine inhibitor dilutions into wells containing DYRK2 reaction reagents, and a plate reader sends the resulting signals to analysis software. The software normalizes the signals to control wells and fits a four-parameter concentration-response curve. When the measurements bracket half-maximal inhibition, the software generates a second plate map with concentrations spaced twofold around the fitted midpoint.
The X position contains a sulfonyl group with two sulfur–oxygen double bonds and one sulfur–carbon bond to each fragment. The two oxygen atoms provide hydrogen-bond acceptor sites.
The R1 amino nitrogen carries methyl at R4 and cyclopropyl at R5. The cyclopropyl group attaches through one of its three ring carbons, and the nitrogen has three carbon bonds.
An oxygen atom connects the scaffold to a methyl group at R2, forming –OCH3. The ether oxygen serves as a hydrogen-bond acceptor adjacent to the scaffold.
The R3 position carries –C(O)OCH2CH3 and attaches to the scaffold through the ester carbonyl carbon. The ester connects the carbonyl carbon to the two-carbon ethyl group through a single oxygen atom.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
As X in formula III, a substituted or unsubstituted lower alkylene group, a substituted or unsubstituted lower alkenylene group, an oxygen atom, a substituted or unsubstituted amino group, a sulfur atom, and a bond are preferable.A · US 2009/0170911 A1 · ¶ 254
As the substituent of the substituted cycloalkyl group, the substituted cycloalkenyl group, the substituted aryl group, the substituted heteroaryl group, and the substituted heterocyclic group in the present invention, for example, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group, a substituted or unsubstituted lower alkynyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkyltA · US 2009/0170911 A1 · ¶ 241
R1 is selected from hydrogen, C1-6 alkyl optionally substituted with one or more deuterium, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-(C3-8 cycloalkyl), —(C1-6 alkyl)-(3-8 membered heterocyclyl), —(C1-6 alkyl)-phenyl, —(C1-6 alkyl)-heteroaryl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, and heteroaryl, wherein each of said C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, andB · US 2022/0315597 A1 · ¶
is 5 membered heteroaryl containing 1, 2, 3, or 4 ring heteroatoms selected from N, O or S; said 5 membered heteroaryl is optionally substituted with one or more substituents independently selected from deuterium, halo, hydroxy, amino, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —CN, mercapto, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxyl, C1-6 haloalkyl, —(C1-6 alkyl)-OH, and —(C1-6 alkyl)-O—(C1-6 alkyl), wherein each of said C1-6 alkyl, C1-6 alkoxyl, and C1-6 haloalkyl is optiB · US 2022/0315597 A1 · ¶
R2 is selected from hydrogen, deuterium, halo, hydroxy, amino, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —CN, mercapto, C1-6 alkyl optionally substituted with one or more deuterium, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-(C3-8 cycloalkyl), —(C1-6 alkyl)-(3-8 membered heterocyclyl), —(C1-6 alkyl)-phenyl, —(C1-6 alkyl)-heteroaryl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, and heteroaryl, wherein each of said CB · US 2022/0315597 A1 · ¶
Z-Y-X- formula III wherein X is any of an oxygen atom, a substituted or unsubstituted amino group, a sulfur atom, and a bond, Y is any of a carbonyl group, a sulfonyl group, and a bond, and Z is any of a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkanoyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a sA · US 2009/0170911 A1 · ¶
R3, R4, R5, R6, R7, and R8 are independently selected from hydrogen, deuterium, halo, hydroxy, —CN, mercapto, amino, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), C1-6 alkyl, —(C1-6 alkyl)-phenyl, C1-6 alkoxyl, and C1-6 haloalkyl; or any two of R3, R4, R5, R6, R7, and R8 together with the carbon atom they are attached to and the B ring form a 8-13 membered spirocyclic, fused, or bridged ring optionally containing 1-3 ring heteroatoms indepeB · US 2022/0315597 A1 · ¶
Z-Y-X- formula III wherein X is any of an oxygen atom, a substituted or unsubstituted amino group, a sulfur atom, and a bond, Y is any of a carbonyl group, a sulfonyl group, and a bond, and Z is any of a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkanoyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a sA · US 2009/0170911 A1 · ¶
An empty cell means only that no passage was reproduced there.
The compounds of the present invention inhibit the physiological activity of lysophosphatidic acid (LPA), and therefore, are useful as agents for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases in which LDA receptor participates.A · US 2009/0170911 A1 · ¶ 3
Particularly, the present compounds are useful as agents for the prophylaxis or treatment of fibrosis of organs (liver, kidney, lung, and the like) or liver diseases.A · US 2009/0170911 A1 · ¶ 3
Accordingly, new compounds and methods for modulating ERK activity and treating related disorders, including cancer, are needed.B · US 2022/0315597 A1 · ¶ 4
The combination approaches with ERK inhibitors were investigated and the pre-clinical data support the combo strategy with other target inhibitors, such as CDK4/6 inhibitor, VEGFR2 inhibitor, PARP inhibitor, multi-ERBB inhibitor and autophagy inhibitor in KRAS mutant cancer cells.B · US 2022/0315597 A1 · ¶ 3
patent.fyi, US 2026/0355194 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355194/, SHA-256 7764d944f43c52aee808c8b8a459949f99e3d7aaca3ae3324908ceb80902fa52